Evidence map›Paper›PMID 37467034›Full record

ArticleJMIR research protocols2023

A "Bundle of Care" to Improve Anticoagulation Control in Patients Receiving Warfarin in Uganda and South Africa: Protocol for an Implementation Study.

Andrea L Jorgensen, Catherine Orrell, Catriona Waitt, Cheng-Hock Toh, Christine Sekaggya-Wiltshire, Dyfrig A Hughes, Elizabeth Allen, Emmy Okello, Gayle Tatz, Giovanna Culeddu and 7 more

Open access · goldAbstract read
In one paragraph

Article in JMIR research protocols, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

Andrea L JorgensenDepartment of Health Data Science, Institute of Population Health Sciences, University of Liverpool, Liverpool, United Kingdom.ORCID https://orcid.org/0000-0002-6977-9337
Catherine OrrellDesmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.ORCID https://orcid.org/0000-0003-1134-7475
Catriona WaittInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0003-0134-5855
Cheng-Hock TohInstitute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.ORCID https://orcid.org/0000-0002-9708-8883
Christine Sekaggya-WiltshireInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0001-9247-2950
Dyfrig A HughesCentre for Health Economics and Medicines Evaluation, School of Health Sciences, Bangor University, Bangor, United Kingdom.ORCID https://orcid.org/0000-0001-8247-7459
Elizabeth AllenDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID https://orcid.org/0000-0003-3064-5267
Emmy OkelloUganda Heart Institute, Kampala, Uganda.ORCID https://orcid.org/0000-0002-6109-0092
Gayle TatzDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID https://orcid.org/0000-0001-5975-3566
Giovanna CuledduCentre for Health Economics and Medicines Evaluation, School of Health Sciences, Bangor University, Bangor, United Kingdom.ORCID https://orcid.org/0000-0001-5032-4255
Innocent G AsiimweThe Wolfson Centre for Personalized Medicine, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.ORCID https://orcid.org/0000-0002-1196-1822
Jerome Roy SemakulaInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0003-3333-8502
Johannes P MoutonDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-3511-1259
Karen CohenDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-1892-4207
Marc BlockmanDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID https://orcid.org/0000-0001-7240-8812
Mohammed LamordeInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID https://orcid.org/0000-0003-2218-6822
Munir PirmohamedThe Wolfson Centre for Personalized Medicine, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.ORCID https://orcid.org/0000-0002-7534-7266
University of Cape Town · ZAUniversity of Liverpool · GBInfectious Diseases Institute · UGBangor University · GBDesmond Tutu HIV Foundation · ZAUganda Management Institute · UG

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundThe quality of warfarin anticoagulation among Sub-Saharan African patients is suboptimal. This is due to several factors, including a lack of standardized dosing algorithms, difficulty in providing timely international normalized ratio (INR) results, a lack of patient feedback on their experiences with treatment, a lack of education on adherence, and inadequate knowledge and training of health care workers. Low quality of warfarin anticoagulation, expressed as time in therapeutic range (TTR), is associated with higher adverse event rates, including bleeding and thrombosis, and ultimately, increased morbidity and mortality. Processes and interventions that improve this situation are urgently needed.

objectiveThis study aims to evaluate the implementation of the "warfarin bundle," a package of interventions to improve the quality of anticoagulation and thereby clinical outcomes. The primary outcome for this study is TTR over the initial 3 months of warfarin therapy.

methodsPatients aged 18 years or older who are newly initiated on warfarin for venous thromboembolism, atrial fibrillation, or valvular heart disease will be enrolled and followed up for 3 months at clinics in Cape Town, South Africa, and Kampala, Uganda, where the warfarin bundle is implemented. A retrospective review of the clinical records of patients on warfarin treatment before implementation (controls) will be used for comparison. This study uses a mixed methods approach of the implementation of patient- and process-centered activities to improve the quality of anticoagulation. Patient-centered activities include the use of clinical dosing algorithms, adherence support, and root cause analysis, whereas process-centered activities include point-of-care INR testing, staff training, and patient education and training. We will assess the impact of these interventions by comparing the TTR and safety outcomes across the 2 groups, as well as the cost-effectiveness and acceptability of the package.

resultsWe started recruitment in June 2021 and stopped in August 2022, having recruited 167 participants. We obtained ethics approval from the University of Cape Town Faculty of Health Sciences Human Research Ethics Committee, the Provincial Health Research Committees in South Africa, the Joint Clinical Research Centre Institutional Review Board, Kampala, and the University of Liverpool Research Ethics Committee. As of February 2023, data cleaning and formal analysis are underway. We expect to publish the full results by December 2023.

conclusionsWe anticipate that the "bundle of care," which includes a clinical algorithm to guide individualized dosing of warfarin, will improve INR control and TTR of patients in Uganda and South Africa. We will use these findings to design a larger, multisite clinical trial across several Sub-Saharan African countries. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/46710.

Indexed as

anticoagulation controldrug monitoringinternational normalized ratioSub-Saharan Africawarfarinwarfarin bundle

Identifiers

PMID37467034
PMCPMC10398551
OpenAlexW4381571097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.